Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors.
drug screen
marizomib
proteasome
rhabdoid tumors
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
10
7
2020
Statut:
epublish
Résumé
Atypical teratoid/thabdoid tumor (AT/RT) remains a difficult-to-treat tumor with a 5-year overall survival rate of 15%-45%. Proteasome inhibition has recently been opened as an avenue for cancer treatment with the FDA approval of bortezomib (BTZ) in 2003 and carfilzomib (CFZ) in 2012. The aim of this study was to identify and characterize a pre-approved targeted therapy with potential for clinical trials in AT/RT. We performed a drug screen using a panel of 134 FDA-approved drugs in 3 AT/RT cell lines. Follow-on in vitro studies used 6 cell lines and patient-derived short-term cultures to characterize selected drug interactions with AT/RT. In vivo efficacy was evaluated using patient derived xenografts in an intracranial murine model. BTZ and CFZ are highly effective in vitro, producing some of the strongest growth-inhibition responses of the evaluated 134-drug panel. Marizomib (MRZ), a proteasome inhibitor known to pass the blood-brain barrier (BBB), also strongly inhibits AT/RT proteasomes and generates rapid cell death at clinically achievable doses in established cell lines and freshly patient-derived tumor lines. MRZ also significantly extends survival in an intracranial mouse model of AT/RT. MRZ is a newer proteasome inhibitor that has been shown to cross the BBB and is already in phase II clinical trials for adult high-grade glioma (NCT NCT02330562 and NCT02903069). MRZ strongly inhibits AT/RT cell growth both in vitro and in vivo via a moderately well-characterized mechanism and has direct translational potential for patients with AT/RT.
Sections du résumé
BACKGROUND
BACKGROUND
Atypical teratoid/thabdoid tumor (AT/RT) remains a difficult-to-treat tumor with a 5-year overall survival rate of 15%-45%. Proteasome inhibition has recently been opened as an avenue for cancer treatment with the FDA approval of bortezomib (BTZ) in 2003 and carfilzomib (CFZ) in 2012. The aim of this study was to identify and characterize a pre-approved targeted therapy with potential for clinical trials in AT/RT.
METHODS
METHODS
We performed a drug screen using a panel of 134 FDA-approved drugs in 3 AT/RT cell lines. Follow-on in vitro studies used 6 cell lines and patient-derived short-term cultures to characterize selected drug interactions with AT/RT. In vivo efficacy was evaluated using patient derived xenografts in an intracranial murine model.
RESULTS
RESULTS
BTZ and CFZ are highly effective in vitro, producing some of the strongest growth-inhibition responses of the evaluated 134-drug panel. Marizomib (MRZ), a proteasome inhibitor known to pass the blood-brain barrier (BBB), also strongly inhibits AT/RT proteasomes and generates rapid cell death at clinically achievable doses in established cell lines and freshly patient-derived tumor lines. MRZ also significantly extends survival in an intracranial mouse model of AT/RT.
CONCLUSIONS
CONCLUSIONS
MRZ is a newer proteasome inhibitor that has been shown to cross the BBB and is already in phase II clinical trials for adult high-grade glioma (NCT NCT02330562 and NCT02903069). MRZ strongly inhibits AT/RT cell growth both in vitro and in vivo via a moderately well-characterized mechanism and has direct translational potential for patients with AT/RT.
Identifiants
pubmed: 32642704
doi: 10.1093/noajnl/vdaa051
pii: vdaa051
pmc: PMC7236404
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdaa051Informations de copyright
© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
Sci Rep. 2017 Dec 15;7(1):17626
pubmed: 29247244
Br J Cancer. 2019 Oct;121(7):545-555
pubmed: 31413318
Nat Rev Cancer. 2011 Jun 09;11(7):481-92
pubmed: 21654818
Sci Rep. 2016 Jan 25;6:18953
pubmed: 26804704
Curr Pharm Des. 2013;19(22):4140-51
pubmed: 23181576
Biochem J. 2013 Sep 1;454(2):201-8
pubmed: 23772801
Neuro Oncol. 2016 Jun;18(6):764-78
pubmed: 26755072
BMC Med Genomics. 2015 Jun 25;8:32
pubmed: 26109171
Cancer Cell. 2016 Dec 12;30(6):891-908
pubmed: 27960086
Genes Chromosomes Cancer. 2013 Feb;52(2):185-90
pubmed: 23074045
J Clin Oncol. 2005 Mar 1;23(7):1491-9
pubmed: 15735125
Cancer Cell. 2019 Feb 11;35(2):204-220.e9
pubmed: 30753823
Cell Death Differ. 2011 Oct;18(10):1584-97
pubmed: 21455219
Oncol Rep. 2008 Nov;20(5):1283-7
pubmed: 18949434
Cancer Cell. 2005 Nov;8(5):407-19
pubmed: 16286248
Sci Transl Med. 2019 Nov 20;11(519):
pubmed: 31748226
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1038-43
pubmed: 16406394
Clin Cancer Res. 2011 Jan 1;17(1):31-8
pubmed: 21208904
Neuro Oncol. 2016 Jun;18(6):840-8
pubmed: 26681765
Curr Cancer Drug Targets. 2011 Mar;11(3):254-84
pubmed: 21247382
J Neurooncol. 2012 Jan;106(2):281-90
pubmed: 21842312
Mol Cell Biochem. 2014 Jan;385(1-2):265-75
pubmed: 24104452
Nucleic Acids Res. 2015 Jul 1;43(W1):W566-70
pubmed: 25969447
Neuro Oncol. 2016 Nov;18(11):1519-1528
pubmed: 27370397
Br J Haematol. 2016 Sep;174(5):711-20
pubmed: 27161872
Br J Haematol. 2017 Apr;177(2):221-225
pubmed: 28387460
J Pediatr Hematol Oncol. 2009 Sep;31(9):651-63
pubmed: 19707161
Curr Mol Med. 2016;16(6):533-44
pubmed: 27211800
Int J Biochem Cell Biol. 2016 Oct;79:403-418
pubmed: 27448843
Neuro Oncol. 2015 Jan;16 Suppl 10:x1-x36
pubmed: 25542864
Pediatr Blood Cancer. 2008 Jan;50(1):37-45
pubmed: 17420992
Oncotarget. 2016 May 17;7(20):29102-15
pubmed: 27074555
J Clin Oncol. 2004 Dec 1;22(23):4804-9
pubmed: 15570082
Cancer Med. 2016 Aug;5(8):1765-75
pubmed: 27228363
Cancer Cell. 2016 Mar 14;29(3):379-393
pubmed: 26923874